Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2010

01-12-2010 | Progress in Hematology

Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia

Author: Yok-Lam Kwong

Published in: International Journal of Hematology | Issue 5/2010

Login to get access

Abstract

Natural killer (NK) cell lymphomas and leukemias are aggressive neoplasms. Clinically, they can be classified into nasal, non-nasal and lymphoma/leukemia subtypes. Treatment results are unfavorable. High-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) may improve patient outcome. For autologous HSCT, a critical review of the literature shows that most patients with nasal NK cell lymphoma in complete remission (CR) appear to do well without HSCT. However, patients with refractory diseases and untreated relapses have poor outcome with HSCT. Therefore, identification of patients with nasal NK cell lymphoma in CR who are at high risk of relapse may be necessary before autologous HSCT can be recommended. Patients with disseminated nasal NK cell lymphoma, non-nasal NK cell lymphoma and NK cell leukemia have poor outcome with autologous HSCT. Allogeneic HSCT may be beneficial to these patients. Most of the reported cases have been performed from HLA-identical sibling donors, and data on alternative HSC sources including matched unrelated donors and umbilical cord blood are very limited. Continuous efforts should be devoted to risk stratification for identifying high-risk individuals for HSCT, and defining the optimal conditioning regimen for NK cell lymphomas.
Literature
1.
Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. Tumours of haematopoietic and lymphoid malignancies. World Health Organization Classification of Tumours. Lyon: IARC Press; 2008. p. 285–8.
2.
Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. Tumours of haematopoietic and lymphoid malignancies. Lyon: IARC Press; 2008. p. 276–7.
3.
Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40:221–32.PubMedCrossRef
4.
5.
Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.PubMedCrossRef
6.
Chim CS, Ooi GC, Shek TW, Liang R, Kwong YL. Lethal midline granuloma revisited: nasal T/Natural-killer cell lymphoma. J Clin Oncol. 1999;17:1322–5.PubMed
7.
Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501–13.PubMed
8.
Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97:821–9.PubMedCrossRef
9.
Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, Gondo H, Hino N, Mori H, Sugimori H, Kawa K, Oshimi K, NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.PubMedCrossRef
10.
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK, Kim BS. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.PubMed
11.
Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182–90.PubMed
12.
Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606.PubMed
13.
Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6.PubMedCrossRef
14.
Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216–21.PubMedCrossRef
15.
Chim CS, Ma ES, Loong F, Kwong YL. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein–Barr virus encoded early small RNA in detecting occult bone marrow involvement. J Clin Pathol. 2005;58:443–5.PubMedCrossRef
16.
Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, Kim WS. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res. 2007;13:3250–4.PubMedCrossRef
17.
Nawa Y, Takenaka K, Shinagawa K, Deguchi S, Matsumura N, Koyama S, Hiramatsu Y, Omoto E, Yoshino T, Harada M. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transpl. 1999;23:1321–2.CrossRef
18.
Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, Yamamoto K, Fujii N, Nawa Y, Hiramatsu Y, Sunami K, Ishimaru F, Yoshimo T, Kiura K, Harada M. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma. 2001;42:1297–303.PubMedCrossRef
19.
Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74:447–50.PubMedCrossRef
20.
Sanda T, Lida S, Ito M, Tsuboi K, Miura K, Harada S, Komatsu H, Wakita A, Inagaki H, Ueda R. Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy. Int J Hematol. 2002;75:195–200.PubMedCrossRef
21.
Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14:1673–6.PubMedCrossRef
22.
Koizumi K, Fujimoto K, Haseyama Y, Endo T, Nishio M, Yokota K, Itoh T, Sawada K, Koike T. Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma. Eur J Haematol. 2004;72:140–4.PubMedCrossRef
23.
Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C, Mukai H, Takenaka K, Yoshino T, Tsuzuki T, Sugimori H, Kawa K, Kodera Y, Oshimi K, NK-cell Tumor Study Group. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transpl. 2006;37:425–31.CrossRef
24.
Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, Lee JH, Ryoo BY, Park YH, Kwon JM, Oh SY, Lee HR, Kim K, Jung CW, Park K, Kim WS. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transpl. 2006;37:819–24.CrossRef
25.
Inoue D, Nagai Y, Takiuchi Y, Nagano S, Arima H, Kimura T, Shimoji S, Mori M, Togami K, Tabata S, Yanagita S, Matsushita A, Nagai K, Maruoka H, Imai Y, Suzuki R, Takahashi T. Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant. Leuk Lymphoma. 2010;51:720–3.PubMedCrossRef
26.
Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, Sakai C, Oshimi K, Kwong YL, Liang R, Yiu H, Wong KH, Cheng HC, Ryoo BY, Suh C, Ko YH, Kim K, Lee JW, Kim WS, Suzuki R. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transpl. 2008;14:1356–64.CrossRef
27.
Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, Yamamoto K, Fujii N, Nawa Y, Hiramatsu Y, Sunami K, Ishimaru F, Yoshimo T, Kiura K, Harada M. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma. 2001;42:1297–303.PubMedCrossRef
28.
Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein–Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet. 1996;347:1124.PubMedCrossRef
29.
Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y, Sugimori N, Zeng W, Wang H, Kotani T, Shiobara S, Matsuda T. Successful treatment of Epstein–Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transpl. 1998;21:1279–82.CrossRef
30.
Makita M, Maeda Y, Takenaka K, Shinagawa K, Sunami K, Hiramatsu Y, Fujii N, Ishimaru F, Ikeda K, Niiya K, Yoshino T, Harada M. Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol. 2002;76:94–7.PubMedCrossRef
31.
Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, Kanda Y, Hirokawa M, Kawabata Y, Matsumura T, Kusumi E, Hirabayashi N, Nagafuji K, Suzuki R, Takeuchi K, Oshimi K. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–7.PubMedCrossRef
32.
Kako S, Izutsu K, Oshima K, Sato H, Kanda Y, Motokura T, Chiba S, Kurokawa M. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:937–9.PubMedCrossRef
33.
Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008;83:721–7.PubMedCrossRef
34.
Wakabayashi S, Arai A, Oshikawa G, Araki A, Watanabe M, Uchida N, Taniguchi S, Miura O. Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy. Int J Hematol. 2009;90:605–10.PubMedCrossRef
35.
Mori Y, Aoki T, Takenaka K, Yamauchi T, Yamamoto A, Kamezaki K, Iwasaki H, Harada N, Miyamoto T, Nagafuji K, Teshima T, Akashi K. Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation. Int J Hematol. 2010;91:107–11.PubMedCrossRef
36.
Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R, Maloney DG. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol. 2010;150:170–8.PubMed
37.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.PubMedCrossRef
38.
Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–9.PubMedCrossRef
39.
Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of l-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006;24:28–32.PubMedCrossRef
40.
Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130:860–8.PubMedCrossRef
41.
Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–20.PubMedCrossRef
Metadata
Title
Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia
Author
Yok-Lam Kwong
Publication date
01-12-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0724-4

Other articles of this Issue 5/2010

International Journal of Hematology 5/2010 Go to the issue

Case Report

Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients

Case Report

Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor

Letter to the Editor

The low expression allele (IVS3-48C) of the ferrochelatase gene leads to low enzyme activity associated with erythropoietic protoporphyria

Letter to the Editor

Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase

Case Report

Lymphadenopathy of IgG4-related sclerosing disease: three case reports and review of literature

Original Article

Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits